CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD

9.88
8.21%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Mind Medicine (MindMed) Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 9.13
Open* 8.81
1-Year Change* 205.9%
Day's Range* 8.81 - 9.97
52 wk Range 2.41-5.01
Average Volume (10 days) 715.00K
Average Volume (3 months) 11.80M
Market Cap 145.54M
P/E Ratio -100.00K
Shares Outstanding 40.09M
Revenue N/A
EPS -1.99
Dividend (Yield %) N/A
Beta -7.16
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 18, 2024 9.88 0.87 9.66% 9.01 10.01 8.79
Mar 15, 2024 9.13 1.12 13.98% 8.01 9.29 8.01
Mar 14, 2024 8.13 -0.93 -10.26% 9.06 9.09 7.89
Mar 13, 2024 8.55 0.58 7.28% 7.97 9.21 7.90
Mar 12, 2024 7.84 -0.49 -5.88% 8.33 8.33 7.53
Mar 11, 2024 8.31 -1.53 -15.55% 9.84 9.86 8.24
Mar 8, 2024 9.65 0.42 4.55% 9.23 10.05 8.75
Mar 7, 2024 8.95 1.56 21.11% 7.39 11.04 7.34
Mar 6, 2024 5.91 -0.09 -1.50% 6.00 6.13 5.82
Mar 5, 2024 5.91 -0.19 -3.11% 6.10 6.34 5.76
Mar 4, 2024 6.19 -0.05 -0.80% 6.24 6.42 5.86
Mar 1, 2024 6.20 0.50 8.77% 5.70 6.24 5.53
Feb 29, 2024 5.69 0.30 5.57% 5.39 5.86 5.39
Feb 28, 2024 5.32 0.22 4.31% 5.10 5.51 4.64
Feb 27, 2024 5.53 0.52 10.38% 5.01 5.64 4.99
Feb 26, 2024 4.95 0.08 1.64% 4.87 5.13 4.86
Feb 23, 2024 4.88 0.20 4.27% 4.68 4.92 4.66
Feb 22, 2024 4.74 0.10 2.16% 4.64 4.88 4.51
Feb 21, 2024 4.59 -0.40 -8.02% 4.99 4.99 4.48
Feb 20, 2024 5.04 0.18 3.70% 4.86 5.33 4.79

Mind Medicine (MindMed) Inc. Subordinate Voting Shares Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

10:59

Country

CA

Event

Q1 2024 Mind Medicine (MindMed) Inc Earnings Release
Q1 2024 Mind Medicine (MindMed) Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 20, 2024

Time (UTC)

14:00

Country

CA

Event

Mind Medicine (MindMed) Inc Annual Shareholders Meeting
Mind Medicine (MindMed) Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Total revenue 0 0 0 0 0
Total Operating Expense 66.331 93.854 33.03 1.10593 5.42921
Selling/General/Admin. Expenses, Total 30.162 59.065 14.399 0.457414 3.10517
Research & Development 32.969 34.789 18.631 2.04904
Depreciation / Amortization 3.2 0.006625 0.275
Interest Expense (Income) - Net Operating
Operating Income -66.331 -93.854 -33.03 -1.10593 -5.42921
Interest Income (Expense), Net Non-Operating 1.69 -0.445 -0.907 0 0.02751
Other, Net 7.845 0.106 0 -0.0725
Net Income Before Taxes -56.796 -94.193 -33.937 -1.10593 -5.47421
Net Income After Taxes -56.796 -93.036 -33.937 -1.10593 -5.47421
Net Income Before Extra. Items -56.796 -93.036 -33.937 -1.10593 -5.47421
Net Income -56.796 -93.036 -33.937 -1.10593 -5.47421
Income Available to Common Excl. Extra. Items -56.796 -93.036 -33.937 -1.10593 -5.47421
Income Available to Common Incl. Extra. Items -56.796 -93.036 -33.937 -1.10593 -5.47421
Diluted Net Income -56.796 -93.036 -33.937 -1.10593 -5.47421
Diluted Weighted Average Shares 30.8575 27.3785 17.7489 0.37943 6.92954
Diluted EPS Excluding Extraordinary Items -1.84059 -3.39815 -1.91206 -2.91472 -0.78998
Diluted Normalized EPS -1.84059 -3.39815 -1.91206 -1.22299 -0.78998
Unusual Expense (Income) 0.64189
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 29.184 20.862 13.9 16.983 16.943
Selling/General/Admin. Expenses, Total 14.407 8.263 5.07 9.211 7.617
Research & Development 13.977 11.799 8.03 6.972 8.526
Operating Income -29.184 -20.862 -13.9 -16.983 -16.943
Interest Income (Expense), Net Non-Operating 1.558 1.232 1.153 0.498 -0.007
Other, Net -1.504 -5.185 7.844 0 -0.007
Net Income Before Taxes -29.13 -24.815 -4.903 -16.485 -16.957
Net Income After Taxes -29.13 -24.815 -4.903 -16.485 -16.957
Net Income Before Extra. Items -29.13 -24.815 -4.903 -16.485 -16.957
Net Income -29.13 -24.815 -4.903 -16.485 -16.957
Income Available to Common Excl. Extra. Items -29.13 -24.815 -4.903 -16.485 -16.957
Income Available to Common Incl. Extra. Items -29.13 -24.815 -4.903 -16.485 -16.957
Diluted Net Income -29.13 -24.815 -4.903 -16.485 -16.957
Diluted Weighted Average Shares 38.5764 38.0773 37.7314 29.2963 28.2434
Diluted EPS Excluding Extraordinary Items -0.75513 -0.6517 -0.12994 -0.5627 -0.60039
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.75513 -0.6517 -0.12994 -0.5627 -0.60039
Depreciation / Amortization 0.8 0.8 0.8 0.8 0.8
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Total Current Assets 146.055 137.215 81.519 2.84093 6.73654
Cash and Short Term Investments 142.142 133.539 80.094 0.017347 3.01645
Cash & Equivalents 0.017347
Short Term Investments
Total Receivables, Net 0.004914
Prepaid Expenses 3.913 3.676 1.425 0.020812 0.0342
Total Assets 169.993 164.002 81.519 2.84093 11.9615
Property/Plant/Equipment, Total - Net 0
Other Long Term Assets, Total 0.331 0
Total Current Liabilities 17.892 10.408 3.008 0.139958 1.9612
Accounts Payable 2.111 4.178 2.022 0.139958 1.9612
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 19.076 12.338 5.651 0.192458 1.9612
Total Long Term Debt 0 0 0 0 0
Total Equity 150.917 151.664 75.868 2.64847 10.0003
Common Stock 0 0 5.37358 15.3218
Additional Paid-In Capital 344.758 288.29 120.22 0.772294
Retained Earnings (Accumulated Deficit) -194.468 -137.672 -44.636 -3.53096 -5.32143
Other Equity, Total 0.627 1.046 0.284 0.033559
Total Liabilities & Shareholders’ Equity 169.993 164.002 81.519 2.84093 11.9615
Total Common Shares Outstanding 37.9791 28.1022 20.96 0.40552 11.0999
Other Liabilities, Total 1.184 1.93 2.643 0.052501 0
Other Current Assets, Total 2.79786 3.6859
Cash 142.142 133.539 80.094 3.01645
Intangibles, Net 3.689 6.869 0 5.225
Goodwill, Net 19.918 19.918 0
Accrued Expenses 5.877 6.23 0.986
Other Current Liabilities, Total 9.904
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 120.086 119.791 132.413 146.055 156.51
Cash and Short Term Investments 117.699 116.895 129.409 142.142 154.519
Cash 117.699 116.895 129.409 142.142 154.519
Prepaid Expenses 2.387 2.896 3.004 3.913 1.826
Other Current Assets, Total 0.165
Total Assets 141.55 142.085 155.529 169.993 180.907
Property/Plant/Equipment, Total - Net
Goodwill, Net 19.918 19.918 19.918 19.918 19.918
Intangibles, Net 1.317 2.108 2.898 3.689 4.479
Total Current Liabilities 31.154 35.121 24.096 17.892 26.038
Accounts Payable 7.686 8.577 2.32 2.111 0.824
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 45.571 36.113 25.185 19.076 27.314
Total Long Term Debt 14.068 0 0 0 0
Deferred Income Tax
Total Equity 95.979 105.972 130.344 150.917 153.593
Common Stock 0 0 0 0 0
Additional Paid-In Capital 361.538 354.023 348.986 344.758 342.415
Retained Earnings (Accumulated Deficit) -266.336 -248.413 -219.283 -194.468 -189.565
Other Equity, Total 0.777 0.362 0.641 0.627 0.743
Total Liabilities & Shareholders’ Equity 141.55 142.085 155.529 169.993 180.907
Total Common Shares Outstanding 40.0947 38.8072 38.2901 37.9791 37.5411
Accrued Expenses 9.957 9.95 6.687 5.877 7.467
Other Liabilities, Total 0.349 0.992 1.089 1.184 1.276
Other Current Liabilities, Total 13.511 16.594 15.089 9.904 17.747
Other Long Term Assets, Total 0.229 0.268 0.3 0.331
Long Term Debt 14.068
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Net income/Starting Line -56.796 -93.036 -33.937 -1.10477 -5.47421
Cash From Operating Activities -50.139 -45.824 -23.597 -0.206066 -3.19971
Cash From Operating Activities 0.006618
Non-Cash Items 7.079 42.716 8.279 0.686323 0.0725
Changes in Working Capital -3.602 3.037 2.061 0.205774 1.927
Cash From Investing Activities 0 -0.297 0 -0.211048
Capital Expenditures -0.310361
Other Investing Cash Flow Items, Total 0 -0.297 0 0.099313
Cash From Financing Activities 59.051 98.824 96.704 0.285516 9.90205
Issuance (Retirement) of Stock, Net 59.458 98.824 97.099 0.285516 9.90205
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects -0.309 0.742 0.284 -0.001382
Net Change in Cash 8.603 53.445 73.391 -0.132972 6.70234
Amortization 3.18 2.616 0 0.275
Deferred Taxes 0 -1.157 0
Financing Cash Flow Items -0.407 0 -0.395
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -24.815 -56.796 -51.893 -35.408 -18.451
Cash From Operating Activities -13.331 -50.139 -37.29 -27.993 -12.866
Amortization 0.791 3.18 2.39 1.6 0.78
Non-Cash Items 8.967 7.079 13.861 8.062 3.792
Changes in Working Capital 1.726 -3.602 -1.648 -2.247 1.013
Cash From Investing Activities 0 0 0 0
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities 0.583 59.051 58.635 0.424 -0.166
Financing Cash Flow Items 0 -0.407 -0.407 -0.407 -0.407
Issuance (Retirement) of Stock, Net 0.583 59.458 59.042 0.831 0.241
Foreign Exchange Effects 0.015 -0.309 -0.365 -0.229 -0.035
Net Change in Cash -12.733 8.603 20.98 -27.798 -13.067
Capital Expenditures
Deferred Taxes 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Samberg (Joseph Daniel) Individual Investor 2.6815 1065000 1065000 2022-09-28 MED
Alyeska Investment Group, L.P. Hedge Fund 2.0066 796962 -245677 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.4298 567885 -6054 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.3181 523522 94219 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9341 371010 30955 2023-06-30 LOW
Horizons ETFs Management (Canada) Inc. Investment Advisor/Hedge Fund 0.5943 236020 -40045 2023-09-30 MED
Busey Wealth Management, Inc. Investment Advisor 0.5195 206320 -38027 2023-09-30 LOW
Sullivan (Mark R) Individual Investor 0.5036 200000 200000 2023-04-13 LOW
Empery Asset Management, L.P. Investment Advisor/Hedge Fund 0.4721 187500 187500 2022-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.4527 179809 859 2023-06-30 LOW
Wernli (Miriam Halperin) Individual Investor 0.4349 172740 100000 2023-03-14 LOW
Cresset Asset Management, LLC Investment Advisor/Hedge Fund 0.4016 159499 159499 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 0.3972 157744 -10441 2023-06-30 HIGH
Liao (Carrie Feng ju) Individual Investor 0.3243 128790 75000 2023-03-14
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3072 122000 0 2023-06-30 LOW
DCVC Management Co, LLC Venture Capital 0.2527 100350 0 2023-06-30 LOW
Telemetry Investments, L.L.C. Hedge Fund 0.2417 96000 -9500 2022-12-31 HIGH
AdvisorShares Investments, LLC Investment Advisor 0.23 91364 -1946 2023-06-30 HIGH
Hu (Cynthia Wong) Individual Investor 0.2014 80000 80000 2022-03-24
Karlin (Daniel Rollings) Individual Investor 0.1841 73114 -6918 2023-09-25 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Mind Medicine (MindMed) Company profile

Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.

Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.

MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.

The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.

In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.

MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.

MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.

Industry: Biotechnology & Medical Research (NEC)

One World Trade Center
Suite 8500
NEW YORK
NEW YORK 10007
US

Income Statement

  • Annual
  • Quarterly

News

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

People also watch

Oil - Crude

81.99 Price
-0.340% 1D Chg, %
Long position overnight fee 0.0269%
Short position overnight fee -0.0488%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,156.24 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

17,937.50 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

64,704.00 Price
-4.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading